Evidence map›Paper›PMID 34862752›Full record

ArticleEMBO molecular medicine2022

Predicting infectivity: comparing four PCR-based assays to detect culturable SARS-CoV-2 in clinical samples.

Emily A Bruce, Margaret G Mills, Reigran Sampoleo, Garrett A Perchetti, Meei-Li Huang, Hannah W Despres, Madaline M Schmidt, Pavitra Roychoudhury, David J Shirley, Keith R Jerome and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. SARS-CoV-2 viral load and shedding kinetics.Nature reviews. Microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emily A Bruce *Division of Immunobiology, Department of Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0001-8391-370X
Margaret G Mills *Virology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-0493-9408
Reigran SampoleoVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Garrett A PerchettiVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Meei-Li HuangVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-2861-8035
Hannah W DespresDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0003-0321-5202
Madaline M SchmidtDepartment of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0003-3893-3466
Pavitra RoychoudhuryVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
David J ShirleyData Science Department, Faraday, Inc., Burlington, VT, USA.
Keith R JeromeVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Alexander L GreningerVirology Division, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-7443-0527
Jason W BottenDivision of Immunobiology, Department of Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA.ORCID 0000-0001-6839-0306

Funding

Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Kristen Pierce · 2018 to 2026
$24.9M
Vermont Immunology/Infectious Diseases CenterP30GM118228 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2016 to 2021
$6.8M
Department of Laboratory Medicine and Pathology, University of WashingtonHHS|NIH|Office of Extramural Research, National Institutes of Health (OER) P30GM118228-04NIGMS NIH HHS P20 GM125498NIGMS NIH HHS P30 GM118228Office of the Vice President for Research, University of Vermont
6 · The paper itself

Abstract

With the COVID-19 pandemic caused by SARS-CoV-2 now in its second year, there remains an urgent need for diagnostic testing that can identify infected individuals, particularly those who harbor infectious virus. Various RT-PCR strategies have been proposed to identify specific viral RNA species that may predict the presence of infectious virus, including detection of transcriptional intermediates (e.g., subgenomic RNA [sgRNA]) and replicative intermediates (e.g., negative-strand RNA species). Using a novel primer/probe set for detection of subgenomic (sg)E transcripts, we successfully identified 100% of specimens containing culturable SARS-CoV-2 from a set of 126 clinical samples (total sgE C

Indexed as

COVID-19SARS-CoV-2HumansPandemicsPolymerase Chain ReactionRNA, ViralRNA, Viralcultureinfectiousnegative-strandSARS-CoV-2subgenomic

Identifiers

PMID34862752
PMCPMC8819313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.